Daiichi Sankyo Company, Limited (DSKYF)
OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
| Previous close | 0.00 |
| Open | 31.90 |
| Bid | 31.25 x 40700 |
| Ask | 35.55 x 40000 |
| Day's range | 31.90 - 31.90 |
| 52-week range | 23.45 - 44.64 |
| Volume | |
| Avg. volume | 2,546 |
| Market cap | 67.286B |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | 44.24 |
| EPS (TTM) | 0.80 |
| Earnings date | 31 Oct 2024 |
| Forward dividend & yield | 0.39 (1.10%) |
| Ex-dividend date | 28 Mar 2025 |
| 1y target est | 48.05 |
ZacksAstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded Use
The FDA grants priority review to AZN's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer. A decision is due in first-quarter 2025.
Business WireENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received at Least One Line of Endocrine Therapy
TOKYO & BASKING RIDGE, N.J., October 01, 2024--ENHERTU Granted Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow mBC Who Have Received at Least One Line of Endocrine Therapy
ZacksAZN Stock Slips as Dato-DXd Cancer Study Misses Survival Goal
AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock falls.
© 2024 Yahoo. All rights reserved.